Barrow Hanley Mewhinney & Strauss LLC Acquires New Position in Bruker Corporation $BRKR

Bruker logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Barrow Hanley Mewhinney & Strauss initiated a Bruker position of 1,014,293 shares, worth about $65.7 million, or approximately 0.66% of the company. Institutional investors and hedge funds collectively own 79.52% of Bruker.
  • Bruker beat quarterly earnings expectations, reporting EPS of $0.56 versus a $0.42 consensus and revenue of $874 million, up 1.6% year over year.
  • Analyst opinion is mixed: the stock has a consensus Hold rating and an average price target of $61. Bruker also announced a quarterly dividend of $0.05 per share, equivalent to a 0.4% annualized yield.
  • MarketBeat previews top five stocks to own in December.

Barrow Hanley Mewhinney & Strauss LLC bought a new position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,014,293 shares of the medical research company's stock, valued at approximately $65,675,000. Barrow Hanley Mewhinney & Strauss LLC owned about 0.66% of Bruker as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Private Wealth Asset Management LLC bought a new stake in shares of Bruker in the 3rd quarter valued at approximately $225,000. USS Investment Management Ltd raised its position in shares of Bruker by 14.9% during the 3rd quarter. USS Investment Management Ltd now owns 174,516 shares of the medical research company's stock valued at $11,298,000 after acquiring an additional 22,677 shares in the last quarter. Focus Advisor Solutions LLC bought a new position in Bruker during the third quarter worth $533,000. Landscape Capital Management L.L.C. bought a new position in Bruker during the third quarter worth $818,000. Finally, Voya Investment Management LLC boosted its holdings in Bruker by 6.2% in the third quarter. Voya Investment Management LLC now owns 9,008 shares of the medical research company's stock worth $583,000 after purchasing an additional 523 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the transaction, the vice president owned 134,806 shares of the company's stock, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 27.20% of the company's stock.

Bruker Stock Down 9.1%

BRKR stock opened at $56.46 on Friday. The stock has a market cap of $8.62 billion, a PE ratio of -51.33, a price-to-earnings-growth ratio of 1.76 and a beta of 1.26. The firm's 50-day simple moving average is $59.99 and its 200 day simple moving average is $51.31. Bruker Corporation has a fifty-two week low of $32.37 and a fifty-two week high of $68.98. The company has a quick ratio of 0.90, a current ratio of 1.84 and a debt-to-equity ratio of 0.74.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.42 by $0.14. Bruker had a negative net margin of 3.82% and a positive return on equity of 13.76%. The firm had revenue of $874.00 million during the quarter, compared to analysts' expectations of $865.16 million. During the same quarter in the prior year, the firm earned $0.45 EPS. Bruker's quarterly revenue was up 1.6% on a year-over-year basis. As a group, sell-side analysts predict that Bruker Corporation will post 2.13 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Monday, December 21st will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, December 21st. Bruker's dividend payout ratio is currently -18.18%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BRKR. The Goldman Sachs Group upgraded shares of Bruker from a "strong sell" rating to a "strong-buy" rating in a research note on Monday, September 21st. Zacks Research downgraded shares of Bruker from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 2nd. Barclays lifted their price target on shares of Bruker from $58.00 to $70.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. TD Cowen boosted their price objective on shares of Bruker from $60.00 to $62.00 and gave the company a "hold" rating in a research report on Tuesday, October 13th. Finally, Royal Bank Of Canada began coverage on shares of Bruker in a research report on Friday. They set a "sector perform" rating and a $66.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $61.00.

Read Our Latest Analysis on BRKR

About Bruker

(Free Report)

Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company's offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.

Featured Articles

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bruker Right Now?

Before you consider Bruker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.

While Bruker currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines